Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PARADIGM
- 04 Sep 2015 Accrual to date is 1% as reported by the United Kingdom Clinical Research Network record.
- 13 Aug 2015 Accrual to date is 0% as reported by United Kingdom Clinical Research Network record.
- 10 Jul 2014 According to the ISRCTN record, trial status is changed from not yet recruiting to recruiting.